Application of lipoic acid modified gold nanoparticles in macrophage polarization and sarcopenia

Inducing macrophage polarization through lipoic acid-modified gold nanoparticles solves the shortcomings of sarcopenia treatment, achieves muscle strength recovery and normalizes skeletal muscle fiber structure, and provides a new therapeutic strategy.

CN119015311APending Publication Date: 2024-11-26BEIJING INST OF TRAUMATOLOGY & ORTHOPEDICS +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411135510.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Sarcopenia is a serious inflammation-related disease with limited existing treatment methods, especially for patients with limited exercise capacity in older patients, there is a lack of effective treatment strategies.

Method used

Gold nanoparticles modified with lipoic acid induce their polarization to anti-inflammatory macrophages (M2 type) through contact with macrophages, thus being used to treat sarcopenia, and their safety and treatment are verified through in vitro and in vivo experiments. Effect.

Benefits of technology

Lipoic acid-modified gold nanoparticles can promote muscle strength recovery and normalize skeletal muscle fiber structure without toxicity, and have significant clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015311A_ABST
    Figure CN119015311A_ABST
Patent Text Reader

Abstract

The invention provides application of lipoic acid modified gold nanoparticles in macrophage polarization and sarcopenia, and relates to the technical field of nano medicine. The application comprises an application of the lipoic acid modified gold nanoparticles in preparation of a preparation for inducing macrophages to be polarized to an M2 type and an application of the lipoic acid modified gold nanoparticles in preparation of a medicine for treating sarcopenia. The application provides a new therapeutic product for treating sarcopenia, and has great practical significance and clinical application value for immunotherapy of sarcopenia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of nanomedicine, and in particular to application of lipoic acid-modified gold nanoparticles in macrophage polarization and sarcopenia. Background Art

[0002] The following statements merely provide background information related to the present disclosure and do not necessarily constitute prior art.

[0003] Sarcopenia is an inflammatory disease that seriously endangers the health of the elderly. It became a formally coded disease in ICD-10 in 2016 (M62.8). Its pathological characteristics are decreased muscle mass, strength and function, which can lead to an increased risk of falls and fractures. It is one of the most common geriatric syndromes. It is estimated that the prevalence rate in people over 65 years old is 10%, and it increases to 30% in people over 80 years old, and is often accompanied by loss of mobility.

[0004] At present, there is a lack of basic research on sarcopenia, the mechanism is still unclear, and there is no clinical drug for sarcopenia. The treatment methods are very limited, mainly through increasing exercise and adjusting nutritional intake, but there are disadvantages such as long treatment cycle and poor treatment effect. In particular, many elderly patients have limited exercise ability (such as fractures, arthritis, etc.), which are not suitable for exercise treatment. Therefore, new treatment strategies are urgently needed.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] The purpose of the present invention is to provide the application of lipoic acid-modified gold nanoparticles in macrophage polarization and sarcopenia, and to provide a new therapeutic product for treating sarcopenia.

[0007] In order to solve the above technical problems, the present invention particularly adopts the following technical solutions:

[0008] In a first aspect, a method for preparing a preparation for inducing macrophage polarization to M2 type is provided.

[0009] In a second aspect, a method for promoting macrophage polarization to M2 type for non-diagnostic and therapeutic purposes is also provided, comprising fully contacting macrophages with lipoic acid-modified gold nanoparticles.

[0010] In a third aspect, the invention also provides the use of lipoic acid-modified gold nanoparticles in the preparation of drugs for treating sarcopenia.

[0011] In a fourth aspect, a drug for treating sarcopenia is also provided, the drug comprising macrophages loaded with lipoic acid-modified gold nanoparticles.

[0012] Compared with the prior art, the present invention has the following beneficial effects:

[0013] The present invention prepares gold nanoparticles modified by lipoic acid of different particle sizes, and incubates with macrophages, and finds that gold nanoparticles modified by lipoic acid can promote macrophages to polarize to anti-inflammatory macrophages (M2 type), wherein the smaller the particle size, the better the effect. By constructing an inflammation-mediated sarcopenia model in vitro, it is proved that M2 type macrophages (induced by gold nanoparticles modified by lipoic acid) have skeletal muscle tropism and the effect of promoting myogenic cell proliferation. Further construct a mouse sarcopenia model, and inject lipoic acid-modified gold nanoparticles or its polarized macrophages in situ into the tibialis anterior muscle of the hind limbs for in vivo experiments. Experimental results show that the in situ injection of lipoic acid-modified gold nanoparticles or its polarized macrophages into sarcopenia model mice can promote the recovery of mouse hind limb muscle strength and the normalization of skeletal muscle fiber structure without producing significant toxicity. Based on the clinical pathological characteristics of long-term chronic and systemic inflammatory state in sarcopenia patients, macrophages in the muscle inflammatory microenvironment are used as therapeutic targets, and lipoic acid-modified gold nanoparticles or their induced polarized macrophages are used to treat sarcopenia, which has great practical significance and clinical application value for the immunotherapy of sarcopenia. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0015] Figure 1 Schematic diagram of 4, 30, 60 and 100 nm lipoic acid-modified gold nanoparticles (LA-Au NPs) prepared in Example 1 (a), representative transmission electron microscopy (TEM) images (b) and diameter distribution are shown in (c), where (b) and (c) are 4, 30, 60 and 100 nm LA-Au NPs from left to right;

[0016] Figure 2 The hydrated diameters of 4, 30, 60, and 100 nm LA-Au NPs prepared in Example 1;

[0017] Figure 3 Zeta potential of 4, 30, 60, and 100 nm LA-Au NPs prepared in Example 1;

[0018] Figure 4UV-visible absorption spectra of 4, 30, 60, and 100 nm LA-Au NPs prepared in Example 1;

[0019] Figure 5 The macrophage cytotoxicity evaluation results of LA-Au NPs of different concentrations and particle sizes in Example 2;

[0020] Figure 6 is the LA-Au NPs uptake by macrophages after macrophages were treated with different concentrations of LA-Au NPs-4 in Example 2;

[0021] Figure 7 is the LA-Au NPs uptake by macrophages after macrophages are treated with LA-Au NPs of different particle sizes in Example 2;

[0022] Figure 8 The changes in morphology and elongation coefficient of macrophages induced by LA-Au NPs of different particle sizes in Example 2 for 12 hours, *p<0.05, ***p<0.001;

[0023] Fig. 9 The changes in morphology and elongation coefficient of macrophages induced by different concentrations of LA-Au NPs-4 for 12 hours in Example 2, *p<0.05, ***p<0.001;

[0024] Fig.10 The changes in macrophage morphology and elongation coefficient induced by LA-Au NPs-4 treatment at different time in Example 2, *p<0.05, ***p<0.001;

[0025] Fig.11 This is the flow cytometry analysis of LA-Au NPs-4-induced macrophage M2 phenotype in Example 2, *p<0.05, ***p<0.001;

[0026] Fig.12 The PCA principal component analysis results of macrophages after induction by LA-Au NPs in Example 2;

[0027] Fig.13 The results of analysis of differentially expressed genes in macrophages after induction by LA-Au NPs in Example 2;

[0028] Fig.14 This is the result of GO functional enrichment analysis of macrophages after induction by LA-Au NPs in Example 2;

[0029] Fig.15 This is the result of GSEA pathway enrichment analysis of macrophages after induction by LA-Au NPs in Example 2;

[0030] Fig.16 The expression of representative marker genes of macrophage M2 polarization after induction by LA-Au NPs in Example 2, *p<0.05, **p<0.01, ***p<0.001;

[0031] Fig.17 The results of the in vitro inflammation-mediated sarcopenia characteristic analysis in Example 3;

[0032] Fig.18 The results of the skeletal muscle tropism analysis of M2 macrophages (induced by LA-Au NPs-4) in Example 3, *p<0.05, **p<0.01;

[0033] Fig.19 The results of the analysis of the pro-myocyte proliferation effect of M2 macrophages (induced by LA-Au NPs-4) in Example 3, *p<0.05, ***p<0.001;

[0034] Fig. 20 This is the experimental process of using LA-Au NPs to treat sarcopenia in Example 4;

[0035] Fig.21 The changes in hematological indicators of the mouse model in Example 4 after treatment with LA-Au NPs or Mac@Au NPs;

[0036] Fig. 22 The changes in body weight, hind limb grip strength, and hind limb grip strength / body weight of the mice in Example 4 after treatment with LA-Au NPs or Mac@Au NPs, *p<0.05, **p<0.01;

[0037] Fig.23 These are the histopathological results of the tibialis anterior muscle after the mouse model in Example 4 was treated with LA-Au NPs or Mac@Au NPs. DETAILED DESCRIPTION

[0038] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0039] Macrophages are an important component of innate immunity and play an important role in the inflammatory response process. They are also the main "target" for nanoparticles to enter the body. In response to different local microenvironments, resting macrophages (M0) can polarize into different phenotypes: pro-inflammatory macrophages (M1 type) and anti-inflammatory macrophages (M2 type), and polarized macrophages can reverse their functions and phenotypes through nanoparticle regulation. Macrophages play an important role in muscles and can regulate processes such as muscle stem cell proliferation and differentiation. Sarcopenia patients are in a state of long-term chronic and systemic inflammation. The continuous high expression of M1 causes an imbalance in the M1-M2 homeostasis, forming an "immune-promoting" microenvironment and inhibiting skeletal muscle regeneration.

[0040] The present invention prepares gold nanoparticles modified with lipoic acid of different particle sizes and incubates them with macrophages, and finds that the gold nanoparticles modified with lipoic acid can promote the polarization of macrophages to anti-inflammatory macrophages (M2 type). By constructing a mouse sarcopenia model, and in situ injecting lipoic acid-modified gold nanoparticles or polarized macrophages induced by it, an in vivo experiment is performed. The experimental results show that in situ injection of lipoic acid-modified gold nanoparticles or polarized macrophages induced by it into sarcopenia model mice can promote the recovery of mouse muscle strength and normalization of muscle fiber structure.

[0041] Based on the above findings, in the first aspect, the use of lipoic acid-modified gold nanoparticles in the preparation of a preparation for inducing macrophage polarization to M2 type is provided.

[0042] In an optional embodiment, the lipoic acid in the lipoic acid-modified gold nanoparticles in the preparation is modified on the surface of the gold nanoparticles via a coordination bond.

[0043] In an optional embodiment, the particle size of the lipoic acid-modified gold nanoparticles in the preparation is 4 to 100 nm, for example, but not limited to, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100 nm.

[0044] In an optional embodiment, the particle size of the lipoic acid-modified gold nanoparticles in the preparation is 4, 30, 60 and 100 nm.

[0045] In an optional embodiment, the working concentration of lipoic acid-modified gold nanoparticles in the preparation is 1 to 100 μg / mL, for example, but not limited to 1, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 μg / mL.

[0046] In an alternative embodiment, the agent is used to polarize resting macrophages (M0 type) into anti-inflammatory macrophages (M2 type).

[0047] In an optional embodiment, the preparation further comprises optional auxiliary materials known in the art, including but not limited to one or more of solvents, buffer components and culture media.

[0048] In a second aspect, a method for promoting macrophage polarization to M2 type for non-diagnostic and therapeutic purposes is also provided, comprising fully contacting macrophages with lipoic acid-modified gold nanoparticles.

[0049] In an optional embodiment, in the method, the lipoic acid in the lipoic acid-modified gold nanoparticles is modified on the surface of the gold nanoparticles via a coordination bond.

[0050] In an optional embodiment, the particle size of the lipoic acid-modified gold nanoparticles in the method is 4 to 100 nm, for example, but not limited to, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100 nm.

[0051] In an optional embodiment, the particle size of the lipoic acid-modified gold nanoparticles in the method is 4, 30, 60 and 100 nm.

[0052] In an optional embodiment, the sufficient contact includes culturing macrophages using a culture medium containing lipoic acid-modified gold nanoparticles. The culture medium can be any culture medium known in the art and can be used to culture macrophages.

[0053] In an optional embodiment, the concentration of lipoic acid-modified gold nanoparticles in the culture medium is 1 to 100 μg / mL, for example, but not limited to 1, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 μg / mL.

[0054] In an alternative embodiment, the method comprises polarizing resting macrophages (M0 type) into anti-inflammatory macrophages (M2 type).

[0055] In a third aspect, the invention also provides the use of lipoic acid-modified gold nanoparticles in the preparation of drugs for treating sarcopenia.

[0056] In an optional embodiment, the drug includes lipoic acid-modified gold nanoparticles, and / or macrophages.

[0057] In an optional embodiment, the lipoic acid-modified gold nanoparticles are loaded into the macrophages.

[0058] In an optional embodiment, the macrophages are fully contacted with the lipoic acid-modified gold nanoparticles to load the lipoic acid-modified gold nanoparticles on the macrophages.

[0059] In an optional embodiment, the M0 type macrophages are fully contacted with lipoic acid-modified gold nanoparticles to load the lipoic acid-modified gold nanoparticles on the macrophages.

[0060] In an optional embodiment, the macrophages are fully contacted with 1-100 μg / mL lipoic acid-modified gold nanoparticles to load the lipoic acid-modified gold nanoparticles on the macrophages. The concentration of the lipoic acid-modified gold nanoparticles can be, for example, but not limited to, 1, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 μg / mL, preferably 20 μg / mL.

[0061] In an optional embodiment, the macrophages are M2 polarized macrophages induced by the lipoic acid-modified gold nanoparticles.

[0062] In an optional embodiment, the macrophages are M0 macrophages that are polarized into M2 macrophages induced by the lipoic acid-modified gold nanoparticles.

[0063] In an optional embodiment, the macrophages are fully contacted with 1-100 μg / mL lipoic acid-modified gold nanoparticles to obtain the M2 polarized macrophages. The concentration of the lipoic acid-modified gold nanoparticles can be, for example, but not limited to, 1, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 μg / mL, preferably 20 μg / mL.

[0064] In an optional embodiment, the lipoic acid in the lipoic acid-modified gold nanoparticles in the drug for treating sarcopenia is modified on the surface of the gold nanoparticles through a coordination bond.

[0065] In an optional embodiment, the particle size of lipoic acid-modified gold nanoparticles in the drug for treating sarcopenia is 4 to 100 nm, for example, but not limited to, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100 nm.

[0066] In an optional embodiment, the particle size of the lipoic acid-modified gold nanoparticles in the drug for treating sarcopenia is 4, 30, 60 and 100 nm.

[0067] In a fourth aspect, a drug for treating sarcopenia is also provided, the drug comprising macrophages loaded with lipoic acid-modified gold nanoparticles.

[0068] In an optional embodiment, the macrophages loaded with lipoic acid-modified gold nanoparticles are macrophages loaded with lipoic acid-modified gold nanoparticles obtained by fully contacting macrophages with lipoic acid-modified gold nanoparticles.

[0069] In an optional embodiment, the macrophages loaded with lipoic acid-modified gold nanoparticles are macrophages loaded with lipoic acid-modified gold nanoparticles obtained by fully contacting M0 macrophages with lipoic acid-modified gold nanoparticles.

[0070] In an optional embodiment, the macrophages loaded with lipoic acid-modified gold nanoparticles are macrophages loaded with lipoic acid-modified gold nanoparticles obtained by fully contacting macrophages with 1 to 100 μg / mL lipoic acid-modified gold nanoparticles. The concentration of lipoic acid-modified gold nanoparticles can be, for example, but not limited to, 1, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 μg / mL, preferably 20 μg / mL.

[0071] In an optional embodiment, the lipoic acid in the drug is modified on the surface of the gold nanoparticles through a coordination bond.

[0072] In an optional embodiment, the particle size of the lipoic acid-modified gold nanoparticles in the drug is 4 to 100 nm, for example, but not limited to, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100 nm.

[0073] In an optional embodiment, the particle size of the lipoic acid-modified gold nanoparticles in the drug is 4, 30, 60 and 100 nm.

[0074] In an optional embodiment, the medicine of the third and fourth aspects also includes a pharmaceutically acceptable carrier and / or excipient. The acceptable carrier and pharmaceutically acceptable excipient can select any conventional carrier and / or excipient known in the art. Including but not limited to solvents, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, anti-caking agents, flavoring agents, antibacterial agents, suspending agents, coating agents, film formers, aromatics, tackifiers, anti-adhesive agents, antioxidants, antioxidant synergists, chelating agents, pH regulators, adsorbents, plasticizers, surfactants, thickeners, inclusion agents, protective agents, humectants, softeners, absorbents, diluents, release regulators, pressure-sensitive adhesives, hardeners, hollow capsules, one or more of matrix and drug carrier materials.

[0075] In an optional embodiment, the dosage form of the medicaments of the third and fourth aspects comprises an injection.

[0076] The present invention is further described below by means of specific examples. However, it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.

[0077] Example 1

[0078] Preparation of lipoic acid modified gold nanoparticles (LA-Au NPs):

[0079] 1. Preparation method:

[0080] Synthesis of 4 nm LA-Au NPs: At room temperature, 20 mL of 2.5 × 10 -4 M HAuCl4 and 2.5×10 -4 1.0 mL of 1 mg / mL lipoic acid solution was directly added to the solution. According to the ligand replacement reaction, the thiol group of lipoic acid will form a coordination bond with the gold atom on the surface of the gold nanoparticles, and replace the citric acid adsorbed by electrostatics, thereby stably modifying the surface of the particles. Stirring was maintained for 3 hours to allow the lipoic acid to be fully modified. The mixed solution was centrifuged at 2000 g / min using a 50 kDa ultrafiltration centrifuge tube to remove excess lipoic acid molecules. The obtained gold nanoparticles were resuspended in 1.0 mL of deionized water and stored at 4 °C.

[0081] Synthesis of 30, 60 and 100 nm LA-Au NPs: First, 150 mL of a solution containing sodium citrate (1.32 mmol / L, i.e., 0.39 mg / mL) was heated to boiling (condensation reflux) for 15 minutes under vigorous stirring. Then, 1.5 mL of HAuCl4 (25 mmol / L, i.e., 10 mg / mL) was added, and within 10 minutes, the color of the solution immediately changed from yellow to blue and finally to pink. Then, the solution was cooled to 90 °C to prevent secondary nucleation during the growth period, and a ~10 nm seed solution was obtained; after seed synthesis, 1 mL of HAuCl4 (25 mmol / L) was injected into the above Au seed solution, stirred for 30 minutes, and then 1 mL of HAuCl4 (25 mmol / L) was added, and stirring continued for 30 minutes; 55 mL of the above sample was taken out, and 53 mL of deionized water and 2 mL of trisodium citrate (60 mmol / L, i.e., 17.65 mg / mL) were added. 1 mL of HAuCl4 (25 mmol / L) was injected into the above solution, stirred for 30 minutes, and then 1 mL of HAuCl4 (25 mmol / L) was added, and stirring continued for 30 minutes; the above steps were repeated continuously until AuNPs with core diameters of 30, 60 and 100 nm were obtained; according to the mass ratio of Au NPs: lipoic acid of 1:1, a lipoic acid solution with a concentration of 1 mg / mL was added, and stirring was maintained for 3 hours; the mixed solution was centrifuged at a speed of 2000 g / min using a 50 kDa ultrafiltration centrifuge tube to remove excess lipoic acid molecules; the obtained gold nanoparticles were resuspended in deionized water and stored at 4°C.

[0082] 2. Characterization of gold nanoparticles:

[0083] The diameter and morphology of gold nanoparticles were observed using a JEM-2100F high-resolution field emission transmission electron microscope (HRTEM) with an accelerating voltage of 200 kV. The HRTEM sample preparation process was to dilute the Au NPs mother solution with water to 20 μg / mL, take 10 μL and place it on a copper grid to dry naturally.

[0084] Dynamic light scattering (DLS) analysis was performed using a Zetasizer to determine the hydrated diameter and Zeta-potential of Au NPs. The stock solution was diluted to 100 μg / mL, and a Malvern-equipped particle size sample cell was used for the hydrated diameter measurement, and a folded capillary cuvette was used for the Zeta-potential measurement.

[0085] The UV-Vis absorption spectrum of Au NPs was collected using a UV-2800 UV-Vis spectrophotometer. The mother solution was diluted to 50 μg / mL, 1.0 mL of the solution was placed in a 1 cm quartz cuvette (slit width: 4 mm), and the spectral information in the range of 400 to 1000 nm was collected at room temperature.

[0086] Schematic diagram of 4, 30, 60, and 100 nm LA-Au NPs. Figure 1 (a) Representative transmission electron microscopy (TEM) images are shown in Figure 1 (b) shows that the particle size distribution is Figure 1 As shown in (c), it can be seen that the particle size distribution of LA-Au NPs is in line with expectations. The hydrated diameter distributions of 4, 30, 60, and 100 nm LA-Au NPs are shown in Figure 2 As shown, the Zeta potential is Figure 3 The UV-visible absorption spectrum is shown in Figure 4 The experimental results show that 4, 30, 60 and 100 nm LA-Au NPs were successfully prepared in this example.

[0087] Example 2

[0088] Polarization effect of lipoic acid-modified gold nanoparticles (LA-Au NPs) on macrophages:

[0089] 1. Cultivation of macrophages:

[0090] Mouse macrophage cell line Raw 264.7 was obtained from the American Type Culture Collection (ATCC). Cells were cultured in a Thermo Forma 311 incubator at 37°C and 5% CO2. The cell culture medium consisted of DMEM basal medium, 10% fetal bovine serum, and 1% penicillin-streptomycin. Raw 264.7 cells are semi-adherent cells and can be harvested directly by gently blowing with a pipette without trypsin digestion.

[0091] 2. Macrophage toxicity test:

[0092] Raw 264.7 cells were seeded in 96-well plates and treated with 0, 0.1, 0.4, 1, 4, 10, 20, 50 and 100 μg / mL of LA-Au NPs (4, 30, 60 and 100 nm) for 24 hours. Cell viability was determined using the Alamar-Blue kit. In brief, the Alamar-Blue reagent was added to the 96-well plate at 10 μL / 100 μL cell culture medium / well. After incubation at 37°C for 3 hours, the fluorescence signal intensity was detected at an excitation / emission wavelength of 560 / 590 nm using a Varioskan Flash multifunctional microplate reader. The results are shown in Figure 2. Figure 5As shown, the results showed that when the concentration was below 100 μg / mL, LA-Au NPs of 4 nm (LA-Au NPs-4), 30 nm (LA-Au NPs-30), 60 nm (LA-Au NPs-60) and 100 nm (LA-Au NPs-100) had no obvious toxicity to macrophages.

[0093] 3. Quantitative analysis of gold nanoparticle uptake by macrophages:

[0094] Raw 264.7 cells (1×10 5 Cells / well) were inoculated in a 12-well plate and cultured for 24 hours. Complete culture medium containing LA-Au NPs of different concentrations (0, 1, 4, 10, 20 μg / mL) and particle sizes (4, 30, 60 and 100 nm) was added to each well and incubated for 24 hours. Then, the cells were harvested, washed, and the gold content was analyzed by inductively coupled plasma mass spectrometry (ICP-MS). Specifically as follows: After LA-Au NPs treatment, the cells were harvested and washed 3 times with PBS and centrifuged at 250g for 3 minutes. 100 μL of aqua regia (concentrated HCl: concentrated HNO3 is 3:1) was added to the cell pellet, digested using a digital metal bath, the temperature was set to 70°C, and digested for 6 hours. The sample was then diluted with 2% HNO3 to a final volume of 1 mL for ICP-MS analysis. ICP-MS analysis was completed using an Agilent 7500 mass spectrometer. For quantitative analysis, monitoring 197 isotopes of Au, and using 89 Y and 115 In was used as an internal standard to correct the drift of the instrument signal. A standard curve was prepared using a standard stock solution of gold (1,000 μg Au / mL, 1.5 mol / L HCl) with concentrations of 0, 10, 20, 50, and 100 ppb. The uptake loading pattern of LA-Au NPs is shown in Figure 6 and Figure 7 As shown, it can be seen that with the increase of LA-Au NPs concentration and particle size, the amount of LA-Au NPs taken up by macrophages increased.

[0095] 4. Morphological analysis of LA-Au NPs-induced macrophage M2 polarization:

[0096] Raw 264.7 cells (1×10 4Cells / well) were seeded in a 96-well plate and cultured for 24 h. Complete culture medium containing LA-Au NPs of different concentrations (1, 10, and 100 μg / mL) and particle sizes (4, 30, 60, and 100 nm) was added to each well and incubated for different times (0, 12, and 24 h). Then, an Olympus IX73 microscope equipped with an ORCA-Flash 4.0LT camera was used to observe the density, morphology, and growth of the cells. The elongation coefficient (ratio of the cell major axis length to the minor axis length) of Raw 264.7 after treatment with different conditions was recorded using a streaking measurement tool to indicate the degree of macrophage M2 polarization. The results are shown in Figure 2. Figure 8 , Fig. 9 and Fig.10 As shown, the results show that the smaller the particle size, the higher the exposure concentration and the longer the exposure time, the higher the degree of induced M2 polarization.

[0097] 5. LA-Au NPs induced macrophage M2 polarization flow cytometry analysis:

[0098] Macrophage polarization induction scheme: cells were cultured in complete medium containing 2ng / mL recombinant mouse IFN-γ and 0.5μg / mL LPS to stimulate the cells to M1 polarization phenotype; cells were cultured in complete medium containing 20ng / mL IL-4 to induce the cells to M2 polarization phenotype. In addition, 20μg / mL 4nm LA-Au NPs were incubated with macrophages to study the effect of LA-Au NPs on macrophage polarization.

[0099] Flow cytometry detection: The above macrophages were collected, stained with CD11c and CD206 for 30 min at room temperature in the dark, washed three times with PBS containing 2% FBS, and analyzed with NovoCyte D1040 flow cytometer for the expression of surface markers of macrophages to determine the degree of M1 and M2 polarization.

[0100] The results are as follows Fig.11 As shown, the results showed that after IFN-γ and LPS induction, the number of macrophages with the M1 macrophage marker CD11c increased significantly; after IL-4 induction, the number of macrophages with the M2 macrophage marker CD206 increased significantly; after 4nm LA-Au NPs induction, the number of macrophages with the M2 macrophage marker CD206 increased significantly, while the number of CD11c macrophages did not change, proving that LA-Au NPs-4 did induce the transformation of macrophages to the M2 phenotype.

[0101] 6.RNA-seq bioinformatics analysis:

[0102] Raw 264.7 cells (1×10 5Cells / well) were inoculated in 12-well plates and cultured for 24 h, and 20 μg / mL LA-AuNPs-4 was incubated with macrophages for 24 h. Then, the cells were harvested, washed, lysed with Trizol, and total RNA was extracted for transcriptome construction and high-throughput sequencing. DESeq2 was used to analyze gene expression changes, and GO functional enrichment analysis and GSEA pathway enrichment analysis were further performed on differentially expressed genes.

[0103] The results are as follows Figure 12-16 As shown, Fig.12 is the result of PCA principal component analysis, Fig.13 The results of differentially expressed gene analysis showed that after induction by 20 μg / mL 4 nm LA-Au NPs, 391 genes were upregulated and 65 genes were downregulated; Fig.14 The results of GO functional enrichment analysis show that the up-regulated genes are mainly enriched in processes such as cell migration, adhesion, tropism, angiogenesis and lipase activity; the results of GSEA pathway enrichment analysis are as follows Fig.15 As shown, it shows that after induction by 20 μg / mL LA-AuNPs-4, the levels of macrophage autophagy, mitochondrial autophagy, fatty acid metabolism, and oxidative phosphorylation increased, which are known typical characteristics of M2 polarization; Fig.16 The results show the expression of representative marker genes of M2 polarization (IL4Rα, CD206, Arg1, Tgfβ1). This result further confirms the effect of LA-Au NPs-4 in inducing macrophage M2 polarization.

[0104] Example 3

[0105] In vitro muscle inflammatory tropism and muscle regeneration effects of macrophages:

[0106] 1. Construction of an Inflammation-Mediated Sarcopenia Model in Vitro

[0107] Myoblast C2C12 cells were plated in 6-well plates with a cell density of about 30%-40%. Normal proliferation medium was added. When the cell density reached about 70%, differentiation medium (DMEM+2% horse serum+1% double antibody) and differentiation medium containing LPS (100ng / mL) or glycerol (1%) were replaced. Differentiation induction was performed for 6 days to construct an inflammation-mediated sarcopenia in vitro model. According to the morphological analysis of the formed myotubes ( Fig.17 ), it can be found that LPS mainly causes skeletal muscle loss by inducing atrophy of myotube width, while glycerol causes a decrease in myotube length and a delay in the formation of myotube differentiation.

[0108] 2. Skeletal muscle tropism of macrophages:

[0109] The tropism of macrophages was investigated by Transwell co-culture experiment. Myoblast C2C12 was plated in 24-well plates with a cell density of about 30%-40%. Normal proliferation medium was added. When the cell density was about 70%, differentiation medium (DMEM+2% horse serum+1% double antibody) and differentiation medium containing LPS (100ng / mL) or glycerol (1%) were replaced. Induction culture was performed for 3 days; then M2 macrophages (induced by 20μg / mL LA-Au NPs-4) were added to the Transwell chamber. After 24h of co-culture, the number of cells in the lower layer of the Transwell chamber was detected. Fig.18 The results showed that simply providing an inflammatory environment had a weak effect on macrophage recruitment, and LPS, as the main component of bacteria, had a strong stimulatory effect on macrophages, reversing the M2 phenotype, while glycerol had no effect; and when C2C12 was present, LPS-induced muscle atrophy inhibited macrophage migration; while glycerol-induced muscle damage promoted macrophage recruitment. Considering that the possibility of sarcopenia being induced by bacterial infection in clinical practice is relatively small, here we ruled out the use of LPS-induced skeletal muscle reduction as a sarcopenia model construction scheme.

[0110] 3. In vitro macrophages promoting muscle regeneration:

[0111] In a 6-well plate, the number of C2C12 cells was fixed in each well, and different proportions of M2 macrophages (induced by 20 μg / mL LA-Au NPs-4) were added for co-culture. After 24 hours, the cells were observed by phase contrast microscopy ( Fig.19 ) found that as the proportion of M2 macrophages increased, the number of C2C12 cells also increased, indicating that M2 macrophages can regulate the proliferation process of C2C12 cells, and it can be found that almost all M2 macrophages are in close physical contact with C2C12 cells, which further indicates the tropism of macrophages.

[0112] Example 4

[0113] Lipoic acid-modified gold nanoparticles (LA-Au NPs) are used to treat sarcopenia. The experimental process is as follows: Fig. 20 As shown;

[0114] 1. Construction of mouse sarcopenia model:

[0115] C57BL / 6J mice (6-8 weeks old, male) were purchased from SBEF (Beijing) Biotechnology Co., Ltd. and housed in Beijing Jishuitan Hospital affiliated to Capital Medical University. The temperature of the house was 20±2°C, the humidity was 50±10%, the light cycle was 7:00-19:00 light, 19:00-7:00 dark, and the specific pathogen-free level (SPF). The sarcopenia mouse model was established, and 50 μL of 50% glycerol (diluted with saline) was injected into the left tibialis anterior muscle (TA) of the mouse. After 7 days, severe inflammatory infiltration, fat infiltration and skeletal muscle reduction were caused; the mice were randomly divided into a sarcopenia model control group and a treatment group, each group containing more than five mice.

[0116] 2. Delivery of treatment plans:

[0117] After incubating Raw 264.7 cells with 20 μg / mL LA-Au NPs-4 for 24 h, the gold nanoparticle-loaded macrophages (Mac@Au NPs) were washed and collected. Afterwards, the macrophages were dispersed in PBS and injected orally into the left tibialis anterior muscle of sarcopenic mice at a rate of 500,000 macrophages / 50 μL / mouse. After 24 hours of treatment with 20 μg / mL LA-Au NPs-4, the mass of Au NPs loaded by 500,000 macrophages was 6.708 μg (see Figure 6 ). To ensure comparability, 500,000 macrophages loaded with an equal mass of LA-Au NPs-4 (6.708 μg) were injected into the left tibialis anterior muscle of sarcopenic mice as the material treatment group. In addition, 50 μL PBS was injected into the left tibialis anterior muscle of sarcopenic mice as the sarcopenia model control group; 50 μL PBS was injected into the left tibialis anterior muscle of normal mice as the normal control group.

[0118] 3. Hematological index detection:

[0119] Blood was drawn through the eyeball, and hematological indicators (blood biochemistry: lactate dehydrogenase, aspartate aminotransferase, uric acid; blood routine: red blood cells, white blood cells, platelets) were tested to verify the in vivo safety of the treatment strategy. Fig.21 The results showed that LA-Au NPs-4 and Mac@Au NPs showed no obvious toxic effects on the heart, liver and kidneys, and did not cause changes in routine blood indicators, proving their in vivo biosafety.

[0120] 4. Muscle mechanics evaluation:

[0121] After 3 weeks of treatment, the mice were weighed using a scale. The muscle mechanics of the mouse hind limbs were tested using a mouse grip strength tester to evaluate the recovery of muscle strength. The mouse hind limb grip strength / body weight was normalized as an indicator of mouse muscle strength. Fig. 22As shown, it can be seen that both LA-Au NPs-4 and Mac@AuNPs can improve the muscle strength of the diseased limbs of the sarcopenia mouse model, and Mac@Au NPs has a better effect in improving sarcopenia in the mouse model.

[0122] 5. Histopathological examination:

[0123] After treatment, the left tibialis anterior muscles of the mice were collected and subjected to H&E staining and histopathological examination. Fig.23 The results showed that the recovery of muscle fiber structure was affected in the untreated group, and cavitation occurred (blue arrow, similar to the structural changes of skeletal muscle caused by aging reported in the literature), while the injection of Au NPs or macrophages tamed in vitro with Au NPs improved the recovery of muscle fiber structure, and the injection of macrophages tamed in vitro had a stronger ability to promote angiogenesis (red arrow).

[0124] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. Application of lipoic acid-modified gold nanoparticles in the preparation of preparations for inducing macrophage polarization to M2 type.

2. The use according to claim 1, characterized in that: Lipoic acid is modified on the surface of gold nanoparticles through coordination bonds; Optionally, the particle size of the lipoic acid-modified gold nanoparticles is 4 to 100 nm; Optionally, the working concentration of lipoic acid-modified gold nanoparticles in the preparation is 1-100 μg / mL.

3. A method for promoting macrophage polarization to M2 type for non-diagnostic and therapeutic purposes, characterized in that: This involves exposing macrophages to sufficient contact with lipoic acid-modified gold nanoparticles.

4. The method according to claim 3, characterized in that Lipoic acid is modified on the surface of gold nanoparticles through coordination bonds; Optionally, in the method, the particle size of the lipoic acid-modified gold nanoparticles is 4 to 100 nm.

5. The method according to claim 3, characterized in that: The sufficient contact includes culturing macrophages with a culture medium containing lipoic acid-modified gold nanoparticles; Optionally, the concentration of lipoic acid-modified gold nanoparticles in the culture medium is 1-100 μg / mL.

6. Application of lipoic acid-modified gold nanoparticles in the preparation of drugs for the treatment of sarcopenia.

7. The use according to claim 6, characterized in that: Lipoic acid is modified on the surface of gold nanoparticles through coordination bonds; Optionally, the particle size of the lipoic acid-modified gold nanoparticles is 4 to 100 nm.

8. The use according to claim 6 or 7, characterized in that: The drug includes lipoic acid-modified gold nanoparticles, and / or macrophages; Optionally, the lipoic acid-modified gold nanoparticles are loaded into the macrophages; Optionally, the macrophages are fully contacted with 1-100 μg / mL lipoic acid-modified gold nanoparticles to load the lipoic acid-modified gold nanoparticles on the macrophages; Optionally, the macrophages are M2 polarized macrophages induced by the lipoic acid-modified gold nanoparticles; Optionally, macrophages are fully contacted with 1-100 μg / mL lipoic acid-modified gold nanoparticles to obtain the M2 polarized macrophages.

9. A drug for treating sarcopenia, characterized in that: Macrophages containing lipoic acid-modified gold nanoparticles.

10. The drug according to claim 9, characterized in that Lipoic acid is modified on the surface of gold nanoparticles through coordination bonds; Optionally, the particle size of the lipoic acid-modified gold nanoparticles is 4 to 100 nm; Optionally, the macrophages loaded with lipoic acid-modified gold nanoparticles are macrophages loaded with lipoic acid-modified gold nanoparticles obtained by fully contacting macrophages with 1 to 100 μg / mL lipoic acid-modified gold nanoparticles; Optionally, the dosage form of the drug includes injection.